Introduction {#S1}
============

Gout is a familiar non-infected auto-inflammatory arthritis, with elevated serum uric acid level and precipitation of monosodium urate (MSU) crystals in the joints and around tissues. About 0.9-2% of adults are suffering from this disease in China and developed countries \[[@ref1]-[@ref4]\]. Although elevated urate demonstrates significant correlation with gout \[[@ref5], [@ref6]\], only about 10% of hyperuricemia patients develop into clinical gout, suggesting that hyperuricemia alone cannot account for the occurrence of gout arthritis \[[@ref7]\]. More and more evidences has indicated that environmental factors, genetic susceptibility, and immune disorders may be responsible for the development of gout arthritis \[[@ref8]\]. Previous genetic researches including genome-wide association studies (GWASs) have identified dozens of loci related with gout flare, in which interleukin (IL)-1β, IL-6, and IL-8 (CXCL8) are involved \[[@ref9]-[@ref13]\].

As the precipitation of MSU crystals in the joint could induce gout flare, which is proved in cell lines and mouse models studies, it is widely recognized that MSU crystals are the endogenous danger signal of the innate immune system components \[[@ref14], [@ref15]\], characterized by the recruitment of neutrophils into the joints. It is thought thatT cells regulate its pathogenesis through proinflammatory cytokines such as IL-1β, tumor necrosis factor (TNF)-α, CXCL8, and IL-6 \[[@ref16], [@ref17]\].

Normally, neutrophils are scarce in synovial fluid, therefore, the enhancement of neutrophil-endothelial adhesion is necessary in acute gout arthritis (GA) onset. At the same time, neutrophil transmigration induced by newly generated neutrophil chemotaxins is similarly necessary in acute gout. The chemotactic factors (CCF) induced by the crystal are assigned to neutrophil chemotactic C-X-C chemokines, in which CXCL8 is involved \[[@ref18]-[@ref20]\]. CXCL8 is rich in the synovia in acute GA, and is responsible for more than 90% of the neutrophil chemotactic activity that gathers in the MSU crystals, stimulated site in vitro \[[@ref21]\].

C-X-C receptor (*CXCR*)-1 and *CXCR2* are specific receptors for the chemokine interleukin 8 (IL-8, CXCL8). Cellular activities of CXCL8 are mediated by *CXCR1* and *CXCR2* (IL-8Rβ), which maintain 78% of amino acid similarity and are encoded by two single-copy genes that are located on chromosome 2q34-35 \[[@ref22]\]. Earlier studies on *CXCR* in gout have been mainly concentrated on animal models about arthritis induced by MSU crystals. Santos *et al*. demonstrated that that IL-1β drives *CXCL1* and consequent *CXCR2*-dependent recruitment of neutrophils \[[@ref23]\]. The inhibition of either receptor was able to reduce the influx of neutrophils and associated pain induced by MSU crystals \[[@ref23]\]. The functional homologue of *CXCR2* was located in the chromosome 1C3 in rats and mice, while *CXCR1* was absent in them. It was proved that *CXCR2* homologue gene knock-out mice can avoid the acute neutrophilic inflammation stimulated by urate crystals \[[@ref24]\]. The function or expression of many inflammatory cytokines may be influenced by the polymorphisms in their gene loci, which may facilitate the susceptibility or severity of inflammatory diseases. Therefore, we hypothesize that the polymorphisms of *CXCR1* or *CXCR2* may be associated with GA. This study was the first to establish an association between GA susceptibility and polymorphisms of *CXCR1* and *CXCR2* in a Chinese Han male population. Follow-up functional studies will be needed to validate these findings.

Material and methods {#S2}
====================

Subjects {#S2_1}
--------

A total of 412 male gout patients, who visited the Department of Gout at the Affiliated Hospital of Qingdao University and the Department of Rheumatology at the Qing Dao Municipal Hospital between December 2013 and June 2015, were recruited. The patients were diagnosed with gout according to the classification criteria established by the American College of Rheumatology (ACR) (1977) \[[@ref25]\]. Patients having a medical history of nephropathy, cancer, hematopathy, autoimmune diseases, other arthritis diseases, or present-day infection were excluded. As the controls, 508 age-matched normal male controls who took regular physical examination at the Affiliated Hospital of Qingdao University between December 2013 and June 2015, with no history of arthritis diseases or systemic inflammatory disease were enrolled in this study at the same time. This study was conducted according to the principles of the Declaration of Helsinki, approved by the Affiliated Hospital, Qingdao University ethical committees, and an informed consent was obtained from all participants.

Examination of regulatory parameters {#S2_2}
------------------------------------

Serum uric acid (sUA), triglycerides (TG), total cholesterol (TC), alanine transaminase (ALT), aspartate transaminase (AST), serum glucose (GLU), and serum creatinine (Scr) were measured by Hitachi model 7600 series automatic analyzer. All measurements were completed by an expert who was blinded to the study in the Clinical Laboratory Department, the Affiliated Hospital of Qingdao University.

DNA isolation and genetic analyses {#S2_3}
----------------------------------

Genomic DNA of the total subjects was isolated from 200 µl whole peripheral blood samples using the TIANamp blood DNA kit (Tiangen Biotech, Beijing, Co., Ltd.). TaqMan probes fluorescence real-time polymerase chain reaction (PCR) were used to detect the polymorphisms of rs2234671, rs1126579, and rs2230054 located in *CXCR1* and *CXCR2*, respectively. Biosystems By Life Technologies (New York, USA) was applied to design and synthesize the primers and TaqMan probes. For rs2234671, the forward primer sequence was 5'-ATGAGGACCCAGGTGATCCAGGAGA-3' and the reverse was 5'-CTGTGAGCGCCGCAACAACATCGGC-3'. For rs1126579, the forward primer sequence was 5'-CAGCCCCCATTGTGGTCACAGGAAG-3' and the reverse was 5'-AGAGGAGGCCACGTTCTTACTAGTT-3'. For rs2230054, the forward primer sequence was 5'-TTGCTGTCGTCCTCATCTTCCTGCT-3' and the reverse was 5'-TGCTGGCTGCCCTACAACCTGGTCC-3'. PCR was carried out in a final reaction volume of 25 µl containing: PCR master mix (2×) 12.5 µl, SNP genotyping assay (20×) 1.25 µl, DNA sample, and DNase-free water 11.25 µl. The amplifications were finished with the conditions as follows: initial denaturation at 95°C for 3 minutes, followed denaturation by 45 cycles at 95°C for 15 seconds and 60°C for 1 minute. During PCR thermal cycle, the fluorescence was detected in real-time. The amplification products were confirmed by sequencing. The genotype discrimination was finally analyzed by Bio-Rad CFX manager 3.0 software.

Statistical analysis {#S2_4}
--------------------

We used SPSS 18.0 to analyze all the results. The Hardy-Weinberg equilibrium (HWE) test in genotype distribution was carried out by using the goodness-of-fit χ^2^ test. The Student's *t*-test was employed to compare the differences in demographic and clinical parameters between two groups. Discrimination in the allelic and genotypic frequencies between cases and controls were assessed using the χ^2^ test with 2 × 2 contingency. Relationships in the genotypes distribution and the allelic frequencies between these two groups were measured by calculating the odds ratios (OR) and 95% confidence intervals (CI) from multivariate logistic regression analysis, with the adjustment for hypertension, diabetes (DM), coronary heart disease (CHD), diastolic blood pressure (DBP), systolic pressure (SBP), waist-hip ratio (WHR), body mass index (BMI), GLU, TG, TC, and age, which were possible confounders. The *p*-values \< 0.05 was considered as statistical significance.

Results {#S3}
=======

Clinical and laboratory characteristics of all the participants studied {#S3_1}
-----------------------------------------------------------------------

The clinical and laboratory characteristics of all the participants of this study are summarized in [Table 1](#T1){ref-type="table"}. There were no differences between GA cases and controls regarding age and gender. GA patients had significantly higher morbidity in DM, CHD, and hypertension than controls. BMI and WHR in GA patients were also much higher than that in the controls. GA patients were shown to have significantly higher sUA, GLU, TG, TC, and ALT, and lower Scr, SBP, and DBP. As for other parameters such as alcohol consumption and smoking, no significant differences were observed between GA patients' group and controls' group.

###### 

Characteristics of gout cases and control study samples (mean ±SD)

  Parameter                      GA (n = 412)    Control (n = 508)   *t or χ^2^*   *p-value*
  ------------------------------ --------------- ------------------- ------------- -----------
  Age (years)                    46.04 ±13.61    46.65 ±10.04        0.761         0.447
  Gender (male/female)           412/0           508/0               --            --
  Alcohol consumption, *n* (%)   200 (48.5)      262 (51.6)          0.836         0.361
  Smoking, *n* (%)               150 (36.4)      209 (41.1)          2.143         0.143
  DM, *n* (%)\#                  38 (9.2)        22 (4.3)            8.933         0.003
  CHD, *n* (%)                   28 (6.8)        4 (0.8)             24.465        0.000
  Hypertension, *n* (%)\*        134 (32.5)      72 (14.2)           44.086        0.000
  BMI (kg/m^2^)                  27.43 ±3.56     25.30 ±3.57         9.038         0.000
  WHR                            0.93 ±0.07      0.90 ±0.06          7.199         0.000
  SBP (mm Hg)                    129.53 ±15.82   135.60 ±20.58       5.056         0.000
  DBP (mm Hg)                    82.61 ±23.18    86.47 ±11.39        3.331         0.001
  sUA (μmol/l)                   514.89 ±85.26   352.85 ±70.17       30.991        0.000
  Scr (μmol/l)                   82.61 ±23.18    86.47 ±11.39        3.096         0.002
  GLU (mmol/l)                   6.08 ±2.49      5.43 ±1.44          4.955         0.000
  TG (mmol/l)                    2.51 ±1.32      1.56 ±1.31          10.848        0.000
  TC (mmol/l)                    5.43 ±1.11      5.28 ±0.99          2.119         0.034
  ALT (U/l)                      34.52 ±23.54    27.52 ±17.60        5.002         0.000
  AST (U/l)                      23.39 ±11.83    23.03 ±11.08        0.474         0.636

\# fasting plasma glucose (FPG) ≥ 7.8 mmol/l or oral glucose tolerance test (OGTT) 2 h plasma glucose ≥ 11.1 mmol/l or ongoing antidiabetics therapy, \* blood pressure ≥ 140/90 mm Hg or ongoing antihypertensive therapy, GA -- gouty arthritis, DM -- diabetes, CHD -- coronary heart disease, BMI -- body mass index, WHR -- waist--hip ratio, SBP -- systolic pressure, DBP -- diastolic blood pressure, sUA -- serum uric acid, Scr -- serum creatinine, GLU -- serum glucose, TG -- triglycerides, TC -- total cholesterol, ALT -- alanine transaminase, AST -- aspartate transaminase

Genetic analysis {#S3_2}
----------------

Genotypic distributions and allelic frequencies of rs2234671, rs1126579, and rs2230054 in GA patients and controls are shown in [Table 2](#T2){ref-type="table"}. The genetic distributions of the three SNPs in controls were in HWE. No significant differences were observed between cases and controls in rs2234671 and rs1126579 genotypic and allelic frequencies. *CXCR2* rs2230054 T included genotypic and T allelic frequencies in gout cases were different from controls significantly (*p* = 0.002 by genotype, *p* = 0.003 by allele). Multivariate logistic regression analysis also suggested that the CC genotype in rs2234671 and rs1126579 do not increase the risk of GA compared with the GG and TT genotype, respectively, while the T genotype included in rs2230054 can decrease the risk of gouty arthritis compared with the CC genotype.

###### 

Allele and genotype frequencies of *CXCR1* and *CXCR2* SNPs in patients with gout arthritis and controls

  Allele/genotype   GA (n = 412) n (%)       Control (n = 508) n (%)   c2      *p-value*   OR (95% CI)        Adjusted OR (95% CI)
  ----------------- ------------------------ ------------------------- ------- ----------- ------------------ ----------------------
  rs2234671                                                                                                   
  GGReference       332 (80.6)               409 (80.5)                ---     ---         1.0                1.0
  GC                77 (18.7)                95 (18.7)                 0.000   0.993       1.00 (0.72-1.39)   1.06 (0.72-1.57)
  CC                3 (0.7)                  4 (0.8)                   0.000   1.000       0.92 (0.21-4.16)   2.09 (0.37-11.69)
  HWE\*             χ^2^ = 0.412 p = 0.814   χ^2^ = 0.354 p = 0.838                                           
  GReference        741 (89.9)               913 (89.9)                ---     ---         1.0                
  C                 83 (10.1)                103 (10.1)                0.002   0.963       0.99 (0.73-1.35)   
  rs1126579                                                                                                   
  TTReference       133 (32.3)               190 (37.4)                ---     ---         1.0                1.0
  TC                201 (48.8)               235 (46.3)                1.826   0.177       1.22 (0.91-1.63)   1.33 (0.94-1.87)
  CC                78 (18.9)                83 (16.3)                 2.310   0.129       1.34 (0.92-1.96)   1.41 (0.89-2.21)
  HWE\*             χ^2^ = 0.018 p = 0.991   χ^2^ = 0.515 p = 0.773                                           
  TReference        467 (56.7)               615 (60.5)                ---     ---         1.0                
  C                 357 (43.3)               401 (39.5)                2.794   0.095       1.17 (0.97-1.41)   
  rs2230054                                                                                                   
  CCReference       361 (87.6)               407 (80.1)                ---     ---         1.0                1.0
  CT                50 (12.1)                99 (19.5)                 9.125   0.003       0.57 (0.39-0.82)   0.50 (0.32-0.77)
  TT                1 (0.3)                  2 (0.4)                   0.000   1.000       0.56 (0.05-6.24)   0.02 (0.001-0.52)
  HWE               χ^2^ = 0.285 p = 0.867   χ^2^ = 0.461 p = 0.292                                           
  CCReference       361 (87.6)               407 (80.1)                                                       
  CT + TT           51 (12.4)                101 (19.9)                9.286   0.002       0.57 (0.40-0.82)   0.47 (0.31-0.74)
  CReference        772 (93.7)               913 (89.9)                ---     ---         1.0                
  T                 52 (6.3)                 103 (10.1)                8.639   0.003       0.60 (0.42-0.85)   

HWE -- Hardy-Weinberg equilibrium

Discussion {#S4}
==========

To our knowledge, this is the first study to reveal the relationship between CXCR SNPs and patients with primary GA in Chinese Han population, which potentially broaden the scope of diseases contributed to CXCR-1 and CXCR-2 SNPs. The direct association of rs2234671 and rs1126579 with gout did not reach significance, which makes us come to the conclusion that these two SNPs may not be genetic risk factors for GA in the studied Chinese Han population. However, the frequencies of the T allele of *CXCR2* rs2230054 was lower in the studied cases than in the controls, which make us believe that the T allele of *CXCR2* rs2230054 may be a protection factor for the development of GA in the studied Chinese Han male population.

The rs2230054 site is a C/T single-nucleotide variation on human chromosome 2, which polymorphism present on *CXCR2* gene Ex3+811C\>T causes an amino acid substitution (L262L) in the CXCR-2 protein. As a common receptor of neutrophil chemotaxis, *CXCR2* rs2230054 polymorphisms was examined in total joint arthroplasty (TJA) patients with prosthetic joint infection (PJI), and no association was found \[[@ref26]\]. However, Hsing *et al*. \[[@ref27]\] verified that rs2230054 genetic variety was associated with the risk of bile duct cancer and biliary stones, when evaluated the role of inflammation-related genes in the development of biliary tract cancer and gallstones. In the present study, we found that T allele of *CXCR2* rs2230054 was related with GA and may be a protection factor for the development of gout. This finding supported the hypothesis that common gene polymorphism in *CXCR2* contribute to the etiology of gout in all mankind.

The etiology of gout is complex and genetic risk factors are involved together with the exposure. As previously described, neutrophils are crucial in the process of gout flare and remission, which are among the first cells to arrive at the inflammation site through chemotaxis coming after senses of danger-associated molecular patterns discharged by injured cells. Chemokine signaling pathway plays an important role in regulating neutrophils trafficking by facilitating the activation, adhesion, crawling, and egress of neutrophils across the endothelial barrier \[[@ref28]\]. Chemokines are small cytokines with low molecular mass (8-10 kDa) and are important mediators with chemotactic and proactivatory effects on varying leukocyte lineages in inflammation. More than 40 chemokines have been identified so far, and CXCL8 is one of the major chemokines that binds to CXCR1 and CXCR2 receptors to activate intracellular signaling pathways, inducing neutrophils' transfer to the inflammation site, and is associated with the initiation and amplification of acute and chronic inflammatory processes. More than 90% of the neutrophils' chemotactic activity accumulating in the MSU crystals stimulated site comes from CXCL8 in vitro \[[@ref21]\]. The *CXCL8* -251T/A (rs4073) polymorphism was reported to be associated with the risk of gout \[[@ref12]\].

CXCR1 belongs to the class A rhodopsin-like G-protein coupled receptor (GPCR) and is in charge of cell signaling. The CXCR1 protein encoded gene lies on 2q35 chromosome consisting of two exons separated by an intron \[[@ref29], [@ref30]\]. CXCR2 is another GPCR molecule, with similar structure and function triggering chemokine signaling through a tyrosine sulfation motif. The gene that encodes CXCR2 protein also lies on the 2q35 chromosome and is composed of 3 exons separated by introns \[[@ref31]\]. CXCR1 and CXCR2 are broadly expressed in immune cells together, including mast cells, neutrophils, and CD8(+) T cells; neutrophils' recruitment can be prevented by non-competitive allosteric inhibitors of these receptors in vivo, which indicate their pivotal role in mediating neutrophils' transfer to acute inflammation sites \[[@ref32]\]. With regard to gout, it was proved that knocking out the murine CXCR-2 homolog (mIL-SRH) can prevent neutrophils from the inflammatory responses to urate crystals in animal models \[[@ref24]\].

Our study on the effect of three SNPs in CXCR in the susceptibility of gout in Chinese Han male population showed lack of significant association between genotypes or allele frequencies of rs2234671 or rs1126579 and gout, whereas rs2230054 polymorphism was associated with the development of gout. However, several limitations about this study should not be neglected. First, all the participants were Chinese Han individuals from Shandong Province and could not represent the whole Chinese population, for regional or racial variation having a crucial effect on gout. Second, *CXCR1* and *CXCR2* genes include numerous variants and only three tag SNPs were selected in the present study, which may give the reason of our failure to find positive outcome in *CXCR1*. Finally, the sample size of this study was limited. Therefore, further well-designed study with different populations, other polymorphisms, and larger sample sizes are needed to further explore the links between CXCR genetic polymorphisms and the development of gout.
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